US FDA approves Takeda, Protagonist's drug for rare blood cancer
28/08/2026 22:37
US FDA approves Takeda, Protagonist's drug for rare blood cancer Aug 28 (Reuters) - The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical 4502.T and Protagonist Therapeutics PTGX.O to treat a rare blood cancer, the health regulator said on Friday.
(Reporting by Kamal Choudhury, Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Vijay Kishore)
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary